Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncternal Therapeutics Inc ONCT

Healthcare Biotechnology
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.


NDAQ:ONCT - Post by User

Oncternal Therapeutics Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by nickmessaro02on Jan 23, 2009 11:23am
520 Views
Post# 15723723

GTX Inc Del Options

GTX Inc Del Options

On 01/23/09 GTX Inc Del options ( GTXI )

are used as an example of market neutral investing

on PERSONALHEDGEFUNDS.COM.

Hedge fund managers use options to increase profits

with limited risk.

The GTX Inc Del example shows how options are

used to generate profits each month from

FEBRUARY 2009 TO MAY 2009

Hedge fund manages use this technique to limit loss

and maximize profit.

Check out how they use GTX Inc Del options

to achieve market neutral investing.

https://www.personalhedgefunds.com

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities